Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How I treat biliary tract cancer
Ángela Lamarca, Julien Edeline, Lipika Goyal
ESMO Open (2022) Vol. 7, Iss. 1, pp. 100378-100378
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 87
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 85
A review of F-18 fluorodeoxyglucose PET/CT in the evaluation and treatment of hepatobiliary tumors
Bradley J. Girod, Asha Kandathil
The Quarterly Journal of Nuclear Medicine and Molecular Imaging (2025) Vol. 68, Iss. 4
Closed Access | Times Cited: 1
New trends in diagnosis and management of gallbladder carcinoma
Efstathios Pavlidis, I. Galanis, T. Pavlidis
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 1, pp. 13-29
Open Access | Times Cited: 11
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer
Chengpei Zhu, Yunchao Wang, Ruijuan Zhu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers
Khine Shan, Tauseef Ur Rehman, S. G. Ivanov, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 1, pp. 624-624
Open Access | Times Cited: 10
Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 9
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Francesca Carosi, Elisabetta Broseghini, Laura Fabbri, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2752-2752
Open Access | Times Cited: 9
Mapping the landscape of biliary tract cancer in Europe: challenges and controversies
Lorenza Rimassa, Shahid A. Khan, Bas Groot Koerkamp, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101171-101171
Open Access | Times Cited: 1
Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma
Yanjie Zhong, Xi-Mei Luo, Fei Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma
Joachim Merters, Ángela Lamarca
Journal of Hepatology (2022) Vol. 78, Iss. 3, pp. 652-657
Open Access | Times Cited: 24
Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view
Jakob M. Riedl, Florian Moik, Tamara Esterl, et al.
Virchows Archiv (2023) Vol. 484, Iss. 2, pp. 169-179
Open Access | Times Cited: 15
Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers
Luccas Lavareze, Talita de Carvalho Kimura, João Figueira Scarini, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids
Ann‐Kathrin Lederer, Nele Görrissen, Tinh Thi Nguyen, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions
Silvia Camera, Federico Rossari, Silvia Foti, et al.
Targeted Oncology (2025)
Closed Access
Factors Contributing to the High Malignancy Level of Cholangiocarcinoma and Its Epidemiology: Literature Review and Data
Xuan Li, Renchu Guan, Shuangquan Zhang
Biology (2025) Vol. 14, Iss. 4, pp. 351-351
Open Access
Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study
Yichen Zheng, Jiamin Guo, Tianhui Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Integrating single-cell RNA sequencing, WGCNA, and machine learning to identify key biomarkers in hepatocellular carcinoma
Gang Wang, Jiaxing Zhang, Yirong Li, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Neoadjuvant Therapy for Extrahepatic Biliary Tract Cancer: A Propensity Score-Matched Survival Analysis
Junya Toyoda, Kota Sahara, T Takahashi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2654-2654
Open Access | Times Cited: 11
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada
Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, et al.
Current Oncology (2023) Vol. 30, Iss. 8, pp. 7132-7150
Open Access | Times Cited: 10
Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications
Stavros P. Papadakos, Ioanna Ε. Stergiou, Nikolina Gkolemi, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3434-3434
Open Access | Times Cited: 9
MicroRNA-451a inhibits gemcitabine-refractory biliary tract cancer progression by suppressing the MIF-mediated PI3K/AKT pathway
Taisuke Obata, Koichiro Tsutsumi, Eijiro Ueta, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 34, pp. 102054-102054
Open Access | Times Cited: 9
SOAT1 in gallbladder cancer: Clinicopathological significance and avasimibe therapeutics
Yuqun Hong, Xiahenazi Abudukeremu, Feifei She, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 6
Closed Access | Times Cited: 2
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
Tiziana Pressiani, Rita Balsano, Laura Giordano, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114196-114196
Closed Access | Times Cited: 2
Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications
Angela Dalia Ricci, Alessandro Rizzo, Annalisa Schirizzi, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3542-3542
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top